CN116075505A - 阿片受体激动剂及其制备方法和用途 - Google Patents

阿片受体激动剂及其制备方法和用途 Download PDF

Info

Publication number
CN116075505A
CN116075505A CN202280003206.2A CN202280003206A CN116075505A CN 116075505 A CN116075505 A CN 116075505A CN 202280003206 A CN202280003206 A CN 202280003206A CN 116075505 A CN116075505 A CN 116075505A
Authority
CN
China
Prior art keywords
mmol
added
reaction
synthesis
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280003206.2A
Other languages
English (en)
Inventor
罗明
聂岳坤
陈海文
李新兴
漆玲波
刘军华
宋志林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tiandi Hengyi Pharmaceutical Co ltd
Original Assignee
Tiandi Hengyi Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tiandi Hengyi Pharmaceutical Co ltd filed Critical Tiandi Hengyi Pharmaceutical Co ltd
Publication of CN116075505A publication Critical patent/CN116075505A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

一类氧杂螺环类小分子化合物、其制备方法及含有该化合物的药物组合物以及其作为MOR受体激动剂和在制备治疗和/或预防疼痛等相关疾病的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202280003206.2A 2021-08-31 2022-08-30 阿片受体激动剂及其制备方法和用途 Pending CN116075505A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111010370X 2021-08-31
CN202111010370 2021-08-31
PCT/CN2022/115846 WO2023030319A1 (zh) 2021-08-31 2022-08-30 阿片受体激动剂及其制备方法和用途

Publications (1)

Publication Number Publication Date
CN116075505A true CN116075505A (zh) 2023-05-05

Family

ID=85410864

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280003206.2A Pending CN116075505A (zh) 2021-08-31 2022-08-30 阿片受体激动剂及其制备方法和用途

Country Status (2)

Country Link
CN (1) CN116075505A (zh)
WO (1) WO2023030319A1 (zh)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5912169B2 (ja) * 2011-03-23 2016-04-27 トレベナ・インコーポレイテッドＴｒｅｖｅｎａ， Ｉｎｃ． オピオイド受容体リガンド並びにそれらの使用方法及び製造方法
CN106588899B (zh) * 2015-10-15 2019-11-15 江苏恒瑞医药股份有限公司 吡啶基取代的6-氧杂螺[4.5]癸烷类衍生物、其制备方法及其在医药上的应用
EP3389657A4 (en) * 2015-12-14 2019-08-07 Trevena, Inc. METHODS OF TREATING HYPERALGESIA
WO2017105881A1 (en) * 2015-12-15 2017-06-22 NeuForm Pharmaceuticals, Inc. Deuterated compounds for treating pain
JP2019503351A (ja) * 2015-12-17 2019-02-07 トレベナ・インコーポレイテッドＴｒｅｖｅｎａ， Ｉｎｃ． オピオイド受容体リガンドおよびシトクロムｐ４５０阻害剤の組合せ
JP6889186B2 (ja) * 2016-07-01 2021-06-18 ノイフォルム・ファーマシューティカルズ・インコーポレイテッドＮｅｕｆｏｒｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 疼痛を治療するための重水素化合物
CN115124520A (zh) * 2017-07-04 2022-09-30 四川海思科制药有限公司 阿片受体激动剂及其应用
US11072601B2 (en) * 2017-09-18 2021-07-27 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. μ-opioid receptor agonist and preparation method therefor and use thereof in field of medicine
CN114269738B (zh) * 2020-08-10 2023-09-29 成都苑东生物制药股份有限公司 一种mor受体激动剂化合物、制备方法及其用途

Also Published As

Publication number Publication date
WO2023030319A1 (zh) 2023-03-09

Similar Documents

Publication Publication Date Title
JP6494624B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
TWI711610B (zh) 布魯頓氏酪胺酸激酶抑制劑
CA2957046C (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
AU2021327397A1 (en) Compounds as glp-1r agonists
BR112020024470A2 (pt) agonistas do receptor de glp-1 e seus usos
KR102336370B1 (ko) 당뇨병과 같은 질환의 치료를 위한 피롤리딘 gpr40 조정제
EP3766882B1 (en) Phthalazine isoxazole alkoxy derivatives, preparation method thereof, pharmaceutical composition and use thereof
CN112430234B (zh) 一种新型kras g12c蛋白抑制剂及其制备方法和用途
PT2090570E (pt) Derivado de imidazole
KR20230124956A (ko) 5원 고리 유도체 및 이의 의학적 용도
EP3442945B1 (en) Tetrahydroisoquinoline derivatives
KR20170033314A (ko) Ｆｓｈｒ의 조절제로서의 피라졸 화합물 및 이의 용도
KR20140014163A (ko) 알파 7 nAChR의 알로스테릭 조절자로서의 (피리딘-4-일)벤질아미드
PT2178858E (pt) Novos compostos heterocíclicos como antagonistas de mglu5
CA3047403A1 (en) Nmda receptor modulators and uses thereof
CA3229591A1 (en) Prodrugs and derivatives of psilocin and uses thereof
EP4079734A1 (en) Triazolopyridazine derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof
CN107849047A (zh) 一种联苯衍生物及其制备方法和在医药上的用途
JP2023538096A (ja) Ｒｅｔキナーゼ阻害剤としてのヘテロ芳香族環化合物及びその製造と使用
JP6900406B2 (ja) Ａｋｔ阻害剤としてのジヒドロピラゾロアゼピン系化合物
CN116075505A (zh) 阿片受体激动剂及其制备方法和用途
BR112013000529B1 (pt) compostos espiro-heterocíclicos como antagonistas mglu5 e composição farmacêutica contendo ditos compostos
CN114907384A (zh) Dna-pk选择性抑制剂及其制备方法和用途
JP2016204374A (ja) 縮合ピラゾール誘導体からなる医薬
CN117263956A (zh) 阿片受体激动剂及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication